LXRX earnings date and last-quarter result: last quarter beat, P/E -31.51. Updated 2026-07-23.
Lexicon Pharmaceuticals (LXRX) Research Hub
Lexicon Pharmaceuticals (LXRX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 1.45 USD (+2.11%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -31.51, market cap 0.98B. This hub links to the full technical, earnings and options research available for LXRX.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.45 USD (+2.11%) |
| 52-week range | 1.37 USD – 2.68 USD |
| Trend regime | Range |
| 14-day RSI | 25 (Oversold) |
| Trailing P/E | -31.51 |
| Market cap | 0.98B |
| Dividend yield | 0.00% |
Available research for LXRX
Covered Call on LXRX: how it works, illustrative setup around the real 1.45 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on LXRX: how it works, illustrative setup around the real 1.45 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on LXRX: how it works, illustrative setup around the real 1.45 USD price, max profit/loss, breakeven and when to use it. Educational.
LXRX technical analysis: range, last 1.45 USD, RSI 25, 52w range 1.37 USD–2.68 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is LXRX in?
Lexicon Pharmaceuticals (LXRX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is LXRX in an uptrend or downtrend?
As of 2026-10-26, LXRX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is LXRX's trailing P/E ratio?
LXRX's trailing P/E is -31.51, with a market cap of 0.98B. See the earnings research page for full valuation detail.